Gain Therapeutics(US:GANX) Globenewswire·2025-09-23 11:40Core Insights - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation allosteric therapies, with its lead drug candidate GT-02287 currently in a Phase 1b clinical trial for Parkinson's disease [4][5] Company Overview - Gain Therapeutics is leading the discovery and development of allosteric small-molecule therapies, utilizing its advanced Magellan™ platform to accelerate drug discovery [4][5] - The company has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors [4] Upcoming Event - Dr. Rinaldo Montalvão, Director of Artificial Intelligence at Gain Therapeutics, will present at the WORLD BI sponsored Drug Discovery Innovation Programme (DDIP) 2025 on September 26, focusing on "Transforming Drug Discovery: Generative Models and Electrostatic Complementarity" [1][2] - The event aims to connect global leaders in the pharma, biotech, and life sciences industries, facilitating networking and knowledge sharing [2][3]